In patients treated with rituximab-containing regimens for chronic lymphocytic leukaemia (CLL) there is no evidence of an association between FcγR polymorphisms and clinical outcomes (85, 86). This evidence concerns the gene FCGR2A and B-cell chronic lymphocytic leukemia.